Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non-Current Assets (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Other Non-Current Assets readings, the most recent being $59.5 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 14.42% to $59.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $59.5 million, a 14.42% increase, with the full-year FY2025 number at $59.5 million, up 14.42% from a year prior.
  • Other Non-Current Assets hit $59.5 million in Q4 2025 for Neurocrine Biosciences, up from $20.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $61.6 million in Q3 2024 to a low of $1.4 million in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $23.2 million (2023), compared with a mean of $28.0 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 621.43% in 2022 and later crashed 69.94% in 2025.
  • Neurocrine Biosciences' Other Non-Current Assets stood at $4.4 million in 2021, then surged by 468.18% to $25.0 million in 2022, then soared by 98.4% to $49.6 million in 2023, then increased by 4.84% to $52.0 million in 2024, then grew by 14.42% to $59.5 million in 2025.
  • The last three reported values for Other Non-Current Assets were $59.5 million (Q4 2025), $20.3 million (Q3 2025), and $21.6 million (Q2 2025) per Business Quant data.